CY1121728T1 - Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα - Google Patents

Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα

Info

Publication number
CY1121728T1
CY1121728T1 CY20191100606T CY191100606T CY1121728T1 CY 1121728 T1 CY1121728 T1 CY 1121728T1 CY 20191100606 T CY20191100606 T CY 20191100606T CY 191100606 T CY191100606 T CY 191100606T CY 1121728 T1 CY1121728 T1 CY 1121728T1
Authority
CY
Cyprus
Prior art keywords
glycosaminoglycan
derivatives
medicines
desulfurized
glucosaminoglycans
Prior art date
Application number
CY20191100606T
Other languages
English (en)
Inventor
Annamaria Naggi
Giangiacomo Torri
Original Assignee
Novahealth Biosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novahealth Biosystems Llc filed Critical Novahealth Biosystems Llc
Publication of CY1121728T1 publication Critical patent/CY1121728T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε Ν-αποθειωμένα και προαιρετικώς 2-Ο-αποθειωμένα παράγωγα γλυκοζαμινογλυκάνης, όπου τουλάχιστον τμήμα των γειτονικών διολών και ΟΗ/ΝΗ2 έχουν μετατραπεί προς την αντίστοιχη αλδεΰδη, οι οποίες αλδεΰδες έχουν στη συνέχεια αναχθεί προς την αντίστοιχη αλκοόλη. Αυτά τα προϊόντα είναι προικισμένα με ανασταλτική δραστικότητα ηπαρανάσης και κατά του όγκου δραστικότητα. Τα εν λόγω παράγωγα γλυκοζαμινογλυκάνης λαμβάνονται από φυσική ή συνθετική γλυκοζαμινογλυκάνη, κατά προτίμηση από μη-κλασματωμένη ηπαρίνη, χαμηλού μοριακού βάρους ηπαρίνες (LMWHs), θειική ηπαράνη ή παράγωγα αυτών. Η εφεύρεση περαιτέρω αφορά στη μέθοδο παρασκευής αυτών και περαιτέρω στη χρήση αυτών ως δραστικά συστατικά φαρμάκων, επίσης σε συνδυασμό με γνωστά καθιερωμένα φάρμακα ή θεραπείες. Η παρούσα εφεύρεση περαιτέρω αφορά σε μία μέθοδο για διάσπαση της διασύνδεσης C2-C3 υπολειμμάτων γλυκοζαμίνης μιας γλυκοζαμινογλυκάνης με οξείδωση της εν λόγω γλυκοζαμινογλυκάνης.
CY20191100606T 2013-10-31 2019-06-07 Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα CY1121728T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000005A ITLO20130005A1 (it) 2013-10-31 2013-10-31 Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
EP14798720.0A EP3063177B1 (en) 2013-10-31 2014-10-23 Derivatives of n-desulfated glycosaminoglycans and use as drugs
PCT/EP2014/072707 WO2015062951A1 (en) 2013-10-31 2014-10-23 Derivatives of n-desulfated glucosaminoglycans and use as drugs

Publications (1)

Publication Number Publication Date
CY1121728T1 true CY1121728T1 (el) 2020-07-31

Family

ID=49683857

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181100940T CY1121087T1 (el) 2013-10-31 2018-09-10 Παραγωγα ν-αποθειωμενων γλυκοζαμινογλυκανων και χρηση ως φαρμακα
CY20191100606T CY1121728T1 (el) 2013-10-31 2019-06-07 Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY181100940T CY1121087T1 (el) 2013-10-31 2018-09-10 Παραγωγα ν-αποθειωμενων γλυκοζαμινογλυκανων και χρηση ως φαρμακα

Country Status (14)

Country Link
US (2) US10875936B2 (el)
EP (2) EP3375792B9 (el)
JP (1) JP6753610B2 (el)
KR (1) KR102007554B1 (el)
CN (2) CN105814086B (el)
CY (2) CY1121087T1 (el)
DK (2) DK3063177T3 (el)
ES (2) ES2687900T3 (el)
HK (2) HK1222873A1 (el)
IT (1) ITLO20130005A1 (el)
PL (2) PL3375792T3 (el)
PT (2) PT3063177T (el)
TR (1) TR201908669T4 (el)
WO (1) WO2015062951A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111670038B (zh) * 2018-02-02 2024-01-26 深圳市海普瑞药业集团股份有限公司 糖胺聚糖衍生物及其制备方法和用途
CN111019014A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种那曲肝素钙的制备工艺
CN114901702B (zh) * 2019-12-27 2024-01-09 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用
WO2024012972A1 (en) 2022-07-14 2024-01-18 Centro Alta Tecnologia Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni S.R.L. Synthetic hexasaccharides mimics of heparin showing heparanase inhibition activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230582B (it) 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
CN1197587C (zh) * 2000-06-09 2005-04-20 中国科学院上海细胞生物学研究所 N-位脱硫酸肝素在预防和治疗炎症中的应用
PT2343077E (pt) * 2001-09-12 2013-08-29 Sigma Tau Res Switzerland Sa Derivados de glicosaminoglicanos totalmente n-dessulfatados como inibidores da heparanase, capazes de atividade antiangiogénica e desprovidos de efeito anticoagulante
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
CN102924627A (zh) * 2012-11-19 2013-02-13 江南大学 一种具有抗肿瘤活性的低抗凝肝素的制备方法

Also Published As

Publication number Publication date
US20200216577A1 (en) 2020-07-09
ES2731582T3 (es) 2019-11-18
PT3063177T (pt) 2018-10-19
TR201908669T4 (tr) 2019-07-22
JP2017507210A (ja) 2017-03-16
CN105814086A (zh) 2016-07-27
EP3375792B9 (en) 2019-11-13
WO2015062951A1 (en) 2015-05-07
DK3375792T3 (da) 2019-06-24
PL3375792T3 (pl) 2019-09-30
EP3063177A1 (en) 2016-09-07
US20160237178A1 (en) 2016-08-18
ES2687900T3 (es) 2018-10-29
JP6753610B2 (ja) 2020-09-09
ITLO20130005A1 (it) 2015-05-01
KR20160105969A (ko) 2016-09-08
PT3375792T (pt) 2019-06-27
EP3063177B1 (en) 2018-08-15
US10875936B2 (en) 2020-12-29
CY1121087T1 (el) 2019-12-11
US20210332162A9 (en) 2021-10-28
US11248063B2 (en) 2022-02-15
CN108912237B (zh) 2021-04-13
DK3063177T3 (en) 2018-10-08
CN108912237A (zh) 2018-11-30
CN105814086B (zh) 2018-09-28
EP3375792A1 (en) 2018-09-19
EP3375792B1 (en) 2019-05-15
HK1254817B (zh) 2020-03-27
US20210054108A2 (en) 2021-02-25
PL3063177T3 (pl) 2018-11-30
KR102007554B1 (ko) 2019-08-05
HK1222873A1 (zh) 2017-07-14

Similar Documents

Publication Publication Date Title
CY1121728T1 (el) Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα
MX2019006868A (es) Derivados de polisacáridos anfifílicos y composiciones que los comprenden.
BR112015028603A2 (pt) método para produção de um produto de biomaterial, e, uso de um material composto
BR112014003477A2 (pt) composições imunoterapêuticas de levedura-muc1 e usos das mesmas
CY1120197T1 (el) Ηπαρινες χαμηλης αντιπηκτικης δρασης
GB2535414A (en) Sanitary tissue products with superior machine direction elongation and foreshortening properties and methods for making same
UY35508A (es) Derivados de oxopiridina sustituidos
WO2012092336A3 (en) Molecular profiling for cancer
CY1122822T1 (el) Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο
MX351104B (es) Nuevos glucosaminoglucanos con baja actividad anticoagulante.
BR112015014876A2 (pt) composições e métodos para aperfeiçoar a solubilidade de rebaudiosídeo x
CY1125071T1 (el) Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη
BR112017005997A2 (pt) método
CY1121515T1 (el) Μεθοδοι και συνθεσεις για την επουλωση πληγων
UA113005C2 (uk) Біотехнологічний хондроїтин-6-сульфат з низькою молекулярною масою для запобігання остеоартриту
BR112015012198A2 (pt) método de preparação de fibras à base do derivado c11-c18 acilatado de hialuronano nos grupos hidroxila do ácido hialurônico, fibra baseada no derivado c11-c18 acilatado de hialuronano nos grupos hidroxila do ácido hialurônico, uso da fibra, têxtil e uso dos têxteis à base das fibras
TR201901472T4 (tr) Kondroitin sülfat ve hiyalüronik asit türevlerini içeren farmasötik formülasyonlar.
WO2013050300A3 (en) Depolymerisation of polysaccharides and related products
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
BR112018009225A2 (pt) conjugados de anticorpo anti-cd22-maitansina e métodos de uso dos mesmos
CY1123044T1 (el) Νεες ενωσεις
BR112018012647A2 (pt) composto, método para tratamento de um hospedeiro, e, uso de um composto.
BR112015013567A8 (pt) extrato de algas que compreende polissacarídeos polianiônicos sulfatados e não sulfatados e suas aplicações.
EA201791294A1 (ru) 7-(МОРФОЛИНИЛ)-2-(N-ПИПЕРАЗИНИЛ)МЕТИЛТИЕНО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ